Q-omics provides the consensus-scored CC2D2A profile across patient tissues and cancer cell-line models. CC2D2A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CC2D2A is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CC2D2A RNA expression shows 20,459 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where CC2D2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CC2D2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CC2D2A survival associations across molecular data types. CC2D2A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CC2D2A RNA expression–survival associations across cancer types. High CC2D2A expression shows unfavorable associations in KICH, UVM, STAD and COAD, but favorable associations in KIRP and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for CC2D2A RNA expression.
This table summarizes CC2D2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CC2D2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CC2D2A shows lower tumor expression in KICH, LUAD, THCA, BLCA, UCEC and LUSC. The KICH box plot shows higher CC2D2A RNA expression in normal versus tumor tissue (log2 FC = −2.542, t-test p < 0.001).
This table shows molecular features associated with CC2D2A in patient tissues and cancer cell lines. In patient samples, CC2D2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CC2D2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BREAST.
